Sexually Transmitted Diseases

HIV training pathways in residency have added 90 HIV physicians to the workforce since 2006.

Funded jurisdictions scramble to meet daunting deadlines yet maintain optimism that the new federal initiative can end flat funding and catalyze progress.

When drug resistance means ART options are exhausted, HIV patients need newer choices. A new study shows that novel prodrug fostemsavir is an effective alternative.

With advancements in antiretroviral therapy, people with HIV are now living longer and developing age-related chronic conditions.

Relying solely on blood tests means clinicians may miss cases of potentially deadly M tuberculosis—and waiting days to treat suspected cases could prove fatal.

Ian Frank, MD, discusses upcoming treatments for people with HIV.

Patients facing HIV stigma may encounter difficulties with retention in care.

George Hanna, MD, vice president and therapeutic head of infectious diseases at Merck Laboratories, discusses data from CROI 2020 on islatravir.

The US government has ambitious goals to expand the number of people tested and treated for HIV in the coming years. A new study details the best interventions to make the biggest difference for the most people.

Ian Frank, MD, explains the "Ending the Epidemic" initiative.

Colleen Kelley, MD, MPH, describes the current state of HIV vaccine efforts.